WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 48.88
-0.74 (-1.49%)
Nov 11, 2026, 4:08 PM HKT
WuXi Biologics Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, WuXi Biologics stock has a consensus rating of "Strong Buy" and an average price target of $60.25. The average 1-year stock price forecast is 23.26% higher than the current stock price, while the lowest is $39.41 (-19.37%) and the highest is $79.67 (+62.99%).
Price Target: $60.25 (+23.26%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for WuXi Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 16 | 17 | 18 | 18 | 18 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 4 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 26 | 27 | 28 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Citi No rating | Citi | Buy Maintains $62.00 | Buy | Maintains | $62.00 | +26.84% | Nov 3, 2026 |
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $64.53 | Buy | Maintains | $64.53 | +32.02% | Sep 18, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $57.00 | Buy | Maintains | $57.00 | +16.61% | Sep 16, 2026 |
Unknown Analyst Zhongtai Securities No rating | Zhongtai Securities | Buy Maintains $61.35 | Buy | Maintains | $61.35 | +25.51% | Sep 5, 2026 |
| UBS | UBS | Buy Reiterates $51.10 → $62.00 | Buy | Reiterates | $51.10 → $62.00 | +26.84% | Sep 1, 2026 |
Financial Forecast
Revenue This Year
25.69B
from 21.79B
Increased by 17.89%
Revenue Next Year
30.71B
from 25.69B
Increased by 19.56%
EPS This Year
1.55
from 1.33
Increased by 16.38%
EPS Next Year
1.86
from 1.55
Increased by 20.07%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.